Glucarpidase allows for outpatient administration of high-dose methotrexate during COVID-19 pandemic

Presenting preliminary data at SNO2020, researchers showed that glucarpidase allows for outpatient administration of high-dose methotrexate (HD-MTX) in patients with CNS lymphoma.

“Patients with CNS lymphoma receiving first-line HD-MTX require hospitalization for monitoring and aggressive hydration to prevent toxicity,” said Dr Lauren Schaff of Memorial Sloan Kettering Cancer Center in New York, New York, USA. However, this may not be possible during the COVID-19 pandemic. “When the local incidence of COVID-19 is high, hospital resources are limited and there is an effort to limit patient contact with the healthcare system,” she said.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.